Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 8033

1.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
[PubMed - indexed for MEDLINE]
2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
3.

Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.

[No authors listed]

Prescrire Int. 2005 Oct;14(79):187-93.

PMID:
16285076
[PubMed - indexed for MEDLINE]
4.

Comparative tolerability profiles of oral antidiabetic agents.

Krentz AJ, Ferner RE, Bailey CJ.

Drug Saf. 1994 Oct;11(4):223-41. Review.

PMID:
7848543
[PubMed - indexed for MEDLINE]
5.

[Treatment of diabetes in metabolic syndrome].

Pelikánova T.

Vnitr Lek. 2009 Jul-Aug;55(7-8):637-45. Review. Czech.

PMID:
19731868
[PubMed - indexed for MEDLINE]
6.

Promising new approaches.

Reasner CA 2nd.

Diabetes Obes Metab. 1999 May;1 Suppl 1:S41-8. Review.

PMID:
11220287
[PubMed - indexed for MEDLINE]
7.
8.

Drug interactions of clinical importance with antihyperglycaemic agents: an update.

Scheen AJ.

Drug Saf. 2005;28(7):601-31. Review.

PMID:
15963007
[PubMed - indexed for MEDLINE]
9.

Effects of current therapeutic interventions on insulin resistance.

Kobayashi M.

Diabetes Obes Metab. 1999 May;1 Suppl 1:S32-40. Review.

PMID:
11220286
[PubMed - indexed for MEDLINE]
10.

Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus.

Evans A, Krentz AJ.

Drug Saf. 1999 Jul;21(1):7-22. Review.

PMID:
10433350
[PubMed - indexed for MEDLINE]
11.

Recent developments and emerging therapies for type 2 diabetes mellitus.

Evans AJ, Krentz AJ.

Drugs R D. 1999 Aug;2(2):75-94. Review.

PMID:
10820647
[PubMed - indexed for MEDLINE]
12.

Oral antidiabetic agents. A guide to selection.

Scheen AJ, Lefèbvre PJ.

Drugs. 1998 Feb;55(2):225-36. Review.

PMID:
9506242
[PubMed - indexed for MEDLINE]
13.

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.

Hermansen K, Mortensen LS.

Drug Saf. 2007;30(12):1127-42. Review.

PMID:
18035865
[PubMed - indexed for MEDLINE]
14.

Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.

Scott LJ, Spencer CM.

Drugs. 2000 Mar;59(3):521-49. Review.

PMID:
10776834
[PubMed - indexed for MEDLINE]
15.

The use of sulphonylureas in the elderly.

Graal MB, Wolffenbuttel BH.

Drugs Aging. 1999 Dec;15(6):471-81. Review.

PMID:
10641958
[PubMed - indexed for MEDLINE]
16.

Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

Wolffenbuttel BH, van Haeften TW.

Drugs. 1995 Aug;50(2):263-88. Review.

PMID:
8521759
[PubMed - indexed for MEDLINE]
17.

Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

Inzucchi SE.

JAMA. 2002 Jan 16;287(3):360-72. Review.

PMID:
11790216
[PubMed - indexed for MEDLINE]
18.

Antihyperglycaemic agents. Drug interactions of clinical importance.

Scheen AJ, Lefèbvre PJ.

Drug Saf. 1995 Jan;12(1):32-45. Review.

PMID:
7741982
[PubMed - indexed for MEDLINE]
19.

Insulin therapy in type 2 diabetes.

Mudaliar S, Edelman SV.

Endocrinol Metab Clin North Am. 2001 Dec;30(4):935-82. Review.

PMID:
11727406
[PubMed - indexed for MEDLINE]
20.

Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.

[No authors listed]

Prescrire Int. 2005 Aug;14(78):133-9.

PMID:
16106595
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk